From yesterday to tomorrow: past, present and future of sequencing - - PowerPoint PPT Presentation

from yesterday to tomorrow past present and future of
SMART_READER_LITE
LIVE PREVIEW

From yesterday to tomorrow: past, present and future of sequencing - - PowerPoint PPT Presentation

From yesterday to tomorrow: past, present and future of sequencing The NGS revolu-on Laurent FARINELLI 19 October 2017 ICCMg2 Second Interna<onal Conference on Clinical Metagenomics Geneva, Switzerland www.fasteris.com Be at the right place


slide-1
SLIDE 1

www.fasteris.com

From yesterday to tomorrow: past, present and future of sequencing

The NGS revolu-on

Laurent FARINELLI 19 October 2017

ICCMg2 Second Interna<onal Conference on Clinical Metagenomics

Geneva, Switzerland

slide-2
SLIDE 2

www.fasteris.com

Be at the right place and =me

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

2

GlaxoWellcome Geneva Biomedical Research Ins<tute

1996

Jonathan Knowles:

Have fun in you work “The right drug for the right pa@ent”

7 instruments ABI 377 Streptococcus pneumoniae

slide-3
SLIDE 3

www.fasteris.com

Bead Arrays

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

3

Lynx Therapeu-cs’ MegaClone Massively Parallel Signature Sequencing (MPSS) Gene Expression Profiling

Brenner, S. et al., Nature Biotechnology 18:630-634 (2000)

September:

I was asked, with Pascal Mayer, to develop faster sequencing

October:

Heard of Bead Arrays: brilliant, but too complicated

slide-4
SLIDE 4

www.fasteris.com

Inven=on of PCR Colonies

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

4

13 November 1996:

Inven-on of PCR Colonies and base-by-base sequencing

slide-5
SLIDE 5

www.fasteris.com

A special day

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

5

13 November 1996:

Inven-on of PCR Colonies and step-by-step sequencing

slide-6
SLIDE 6

www.fasteris.com

Two patents filed

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

6

By X’Mas:

Proof-of-principles

1 April 1997:

Two Patents filed

slide-7
SLIDE 7

www.fasteris.com

PCR Colonies project

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

7

1996-1997

GlaxoWellcome

1998-2000

Serono

2001-2003

GenInEx / Manteia Predic=ve Medicine With your genome on CD you consult our database to predict response to treatment or risk of disease

Library prepara-on,

including Y-shaped adapter (Laurent) and P5, P7 (Magne)

Instrument (Microscope and flow-cell) Reverse terminator sequencing chemistry Sodware for real--me DNA colonies detec-on and base-calling

2004-2006

Solexa & Lynx Therapeu-cs ($4 M)

2007-

illumina ($600 M)

A A T T

slide-8
SLIDE 8

www.fasteris.com

2003, Fasteris

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

8 Everything started in a chalet...

slide-9
SLIDE 9

www.fasteris.com

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

9

Library Preparation Kit Solexa Genome Analyzer Solexa Cluster Station

NGS Pioneers

Data analysis

slide-10
SLIDE 10

www.fasteris.com

2007 installa=on run

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

10

Staphylococcus aureus for HUG Genomic Laboratory 8 lanes of 500’000 reads of 26 bases Difficult to analyze data:

I had to use mySQL database to sort reads

I could easier assemble

genomes using EDENA than map on reference

Plasmid NOT included in the reference sequence => artefact and false SNPs

slide-11
SLIDE 11

www.fasteris.com

NGS Pioneers

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

11

We developed:

Genomes de novo assembly

  • f transcriptome

ChIP-SEQ

Bar-coded small RNAs

At the end of 2007, proud to be considered by illumina

First service lab to buy the machine Smallest lab to use the technology The lab that developed the broadest range of applica-ons

100 200 300 400 500 600 700 800 5000000 10000000 15000000 20000000 25000000 Position on the Reference Sequence Number of Mapped Reads

Microsporidia

slide-12
SLIDE 12

www.fasteris.com

Today applica=ons

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

12

Medical diagnos-cs

Under Swiss law for gene-cs

Bestsellers

Batches every 1-2 weeks Stable protocols, short TAT, lower cost, higher volumes

Personalized

1-2 batch per month Many op-ons, partnership with researchers

Research

Developing new protocols

slide-13
SLIDE 13

www.fasteris.com

Medical applica=ons

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

13

Non-invasive prenatal test (NIPT) Soma-c Cancer Panels Germline Cancer Panels

Preimplanta-on Diagnos-c (PGD-A)

2017: Fasteris accredita-on

and gene-cs authoriza-on

2013: Whole genome 2015: Reimbursed T13, 18, 21

slide-14
SLIDE 14

www.fasteris.com

Bestsellers applica=ons

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

14

Genomes Exomes

Transcriptomes

Small RNA

slide-15
SLIDE 15

www.fasteris.com

Personalized applica=ons

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

15

Many different protocols Several op-ons, e.g. Ribozero to eliminate host and

bacterial rRNA MetaFAST

Research

Custom protocols

slide-16
SLIDE 16

www.fasteris.com

2008 NGS Metagenomics

First metagenomics paper using illumina NGS? Genomic Research Laboratory University Hospital of Geneva

Oral samples, amplicons of the 16S rRNA V5 variable region

25 January 2017 Laurent Farinelli – Université Paris Descartes (c) 2017, Fasteris SA

16

slide-17
SLIDE 17

www.fasteris.com

Clinical Metagenomics

Collabora=on with

Impact on survival ader cys-c fibrosis lung transplant Looking for viruses in glioblastoma Shotgun approach to find viruses and fungi

Collabora=on with

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

17

slide-18
SLIDE 18

www.fasteris.com

Metagenomics protocols

IMPORTANT NOTICE

This document provides information for an application for Illumina technology that has been demonstrated internally and may be of interest to customers. This information is provided as‐is and is not an Illumina product and is not accompanied by any rights or

  • warranties. Customers using or adapting this information should obtain any licenses

required and materials from authorized vendors. Illumina products mentioned herein are for research use only unless marked otherwise. While customer feedback is welcomed, this application is not supported by Illumina Technical Support and Field Application Scientists. Part # 15044223 Rev. B

Page 1

16S Metagenomic Sequencing Library Preparation

Preparing 16S Ribosomal RNA Gene Amplicons for the Illumina MiSeq System

Introduction 2 16S Library Preparation Workflow 5 Amplicon PCR 6 PCR Clean‐Up 8 Index PCR 10 PCR Clean‐Up 2 13 [Optional] Validate Library 15 Library Quantification, Normalization, and Pooling 16 Library Denaturing and MiSeq Sample Loading 17 MiSeq Reporter Metagenomics Workflow 20 Supporting Information 21 Figure 1 16S V3 and V4 Amplicon Workflow User‐defined forward and reverse primers that are complementary upstream and downstream of the region of interest are designed with overhang adapters, and used to amplify templates from genomic

  • DNA. A subsequent limited‐cycle amplification step is performed to add multiplexing indices and

Illumina sequencing adapters. Libraries are normalized and pooled, and sequenced on the MiSeq system using v3 reagents.

Amplicon Primers

  • The gene‐specific sequences used in this protocol target the 16S V3 and V4 region. They

are selected from the Klindworth et al. publication (Klindworth A, Pruesse E, Schweer T, Peplles J, Quast C, et al. (2013) Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next‐generation sequencing‐based diversity studies. Nucleic Acids Res 41(1).) as the most promising bacterial primer pair. Illumina adapter

  • verhang nucleotide sequences are added to the gene‐specific sequences. The full length

primer sequences, using standard IUPAC nucleotide nomenclature, to follow the protocol targeting this region are: 16S Amplicon PCR Forward Primer = 5' TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG 16S Amplicon PCR Reverse Primer = 5' GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC

  • This method can also be utilized to target other regions on the genome (either for 16S

with other sets of primer pairs, or non‐16S regions throughout the genome; ie any amplicon). The overhang adapter sequence must be added to the locus‐specific primer for the region to be targeted (Figure 1). The Illumina overhang adapter sequences to be added to locus‐specific sequences are: Forward overhang: 5’ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG‐[locus‐ specific sequence] Reverse overhang: 5’ GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG‐[locus‐ specific sequence]

Introduction Page 3

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

18

1-step PCR

Using primers with long tags (>60 nucleo-des) Advantage:

  • Add the en-re illumina adapter sequence

in one step. Inconvenient:

  • Long primers

Expensive and significant impact on amplifica-on efficiency

2-steps PCR

1st step with primers with medium tag (30 nt) 2nd step with illumina primers Advantage:

  • Only one primer pair needed for 1st step.

Inconvenient:

  • 2 PCR reac-ons needed

Libraries with low complexity

All inserts in the same orienta-on with similar sequences => Impact on sequence quality

slide-19
SLIDE 19

www.fasteris.com

MetaFast

Developed by Fasteris

tag 1 specific primer 1 specific primer 2 tag 2

Step 1: PCR using primers with short tags Step 2: Normalization and pooling Step 3: End-repair, A-tailing and TruSeq adapter ligation

Tags 1 NNAACCGT 2 NNCGATGT 3 NNNGTGAGC 4 NNNTCCGCT 5 NNNNACAGTG 6 NNNNCTTGTA 7 NNGACTCT 8 NNTGACCA 9 NNNATCACG 10 NNNCCGGAG 11 NNNNGGCTAC 12 NNNNTAGCTT 13 NNACTTGA 14 NNCAGATC 15 NNNGGTATA 16 NNNTTTAGG 17 NNNNAGAAGA 18 NNNNGATCAG 19 NNTTGTTC 20 NNATTCGC 21 NNNCGTTAA 22 NNNGAGGAT 23 NNNNTTAGGC 24 NNNNGCCAAT

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

19

slide-20
SLIDE 20

www.fasteris.com

Improvements by MetaFast

  • Standard library prepara=on (Nano)

≈ 10% chimera

  • Standard without PCR

≈ 1% chimera

  • MetaFast (modified end-repair)

≈ 0.1% chimera

TagF1 TagF2 TagF3 TagF4 TagF5 TagF6 TagF7 TagF8 TagR1

90.44 99.76 1.61 0.04 0.89 0.02 1.37 0.06 1.79 0.02 1.49 0.03 1.1 0.02 1.32 0.05

TagR2

1.24 0.03 90.51 99.8 1.1 0.02 1.44 0.05 2.08 0.03 1.21 0.03 0.96 0.01 1.45 0.03

TagR3

1.13 0.03 1.62 0.02 90.16 99.82 1.61 0.04 1.82 0.02 1.24 0.04 0.96 0.02 1.46 0.02

TagR4

0.83 0.01 1 0.01 0.83 93.39 99.92 1.42 0.03 0.85 0.01 0.68 0.99 0.01

TagR5

1.03 0.03 1.47 0.02 0.92 0.01 1.42 0.04 91.69 99.83 1.05 0.02 0.83 0.02 1.6 0.03

TagR6

1.47 0.04 1.28 0.02 0.87 0.02 1.32 0.07 1.64 0.04 90.88 99.71 1.2 0.07 1.32 0.04

TagR7

1.72 0.03 1.7 0.02 1.22 0.02 1.59 0.05 2.06 0.03 1.78 0.04 88.01 99.75 1.94 0.06

TagR8

1.16 0.04 1.64 0.03 0.96 0.02 1.54 0.04 2.36 0.02 1.32 0.03 1.19 0.01 89.84 99.82

With 5 cycles PCR MetaFast (no PCR)

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

20

Samples 1 – 8, Fwd Tag Rev Tags Found

slide-21
SLIDE 21

www.fasteris.com

Advantages of MetaFast

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

21

Op-mized pipeline for large number of samples

Large number of PCRs can be pooled to prepare a single illumina library

Improved quality

Short tags on primers:

Very low incidence on amplifica-on efficiency

Insert present in both forward and reverse orienta-on:

Increases sequence variability

Reduced chimera

Lower cost

slide-22
SLIDE 22

www.fasteris.com

Future of NGS

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

22

When looking at the last 10 years, we can clearly speak

  • f a revolu-on

Speed and cost

slide-23
SLIDE 23

www.fasteris.com

Future of NGS and Metagenomics

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

23

Sequencing speed

4 10 300 50 100 150 200 250 300 350 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 Year Bases / sec

7 instruments ABI 377 1 setup ABI 3730xl Solexa 1G

slide-24
SLIDE 24

www.fasteris.com

Tremendous speed increase

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

24

Sequencing speed

10000 20000 30000 40000 50000 60000 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Year Bases / sec

7 instruments ABI 377 1 setup ABI 3730xl GA 1G GA II P-E GA IIx Pipeline 1.6 GA II Pipeline 1.4

slide-25
SLIDE 25

www.fasteris.com

Tremendous speed increase

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

25

Sequencing speed

100000 200000 300000 400000 500000 600000 700000 800000 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Q2, 2010 Q2, 2011 Year Bases / sec

7 instruments ABI 377 1 setup ABI 3730xl GA 1G GA II P-E GA IIx Pipeline 1.4 and 1.6 HiSEQ-2000 June 2010 HiSEQ-2000 June 2011 HiSEQ-2500 1Tb Mid-2014

1.9 mio

bases per second

NovaSeq 2017

19 mio

bases per second

slide-26
SLIDE 26

www.fasteris.com

Future of NGS

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

26

When looking at the last 10 years, we can clearly speak

  • f a revolu-on

Speed and cost It’s becoming cheaper to generate data than to store it We see now incredible growth in medicine Challenges as well, in par-cular for

Quality and Valida-on of data, CE-IVD, accredita-on Trend for automa-zed “For Diagnos-cs” systems

=> Importance of analysis

slide-27
SLIDE 27

www.fasteris.com

Future of NGS

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

27

Changing role for doctors, who cannot know everything

Partnership with pa-ents Importance of Human experience

Screening everywhere?

=> What about the right of NOT knowing?

It is our responsibility to apply this technology

for the good of humankind and not for profit

slide-28
SLIDE 28

www.fasteris.com

Future of Metagenomics

19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

28

We are discovering new universes We are discovering how bacteria manipulate us It is just the beginning, many surprises can be expected More data and longer reads, in complement to other

informa-on, will help us to understand microbial communi-es, to improve

Environment, Food, Well-being, .. ..and Health, through the clinical applica-ons

that we’ll hear about during ICCMg2 !

When will we be able to manipulate

sustainably microbial communi-es?

slide-29
SLIDE 29

www.fasteris.com

Fasteris team

Sales & Marketing

Axel STRITTMATTER François ALLER Svetlana SKARUPELOVA Aneliya ETROPLOSKA

NGS Production

Cécile DELUEN SAGNE Christelle BARRAS Elisabeth DIETERLE ZARE Cristel BUSCA Franz PELEGRIN Sonia PERREIRA Vianney FRIGARD Fanny JOLY

Sanger Sequencing

Anne SCHOENDORF Chloé HOT Christophe BUSER

Bioinformatics & IT

Loïc BAERLOCHER Gérald BLANC Manuele CASTELNUOVO Nicolas GONZALEZ Patricia OTTEN

Administration

Laurent FARINELLI Isabelle LOROLE

Quality

Gilles MATTON Benoît WINIGER

Development

Marta COTADO Pauline CHARRUAU

Research

Nadine VINCENT Magne OSTERAS

Diagnostics / FAMH

Frédéric GUERRY (AUR) Marco BELFIORE (MCL) Fabien MURISIER (FER) 19 October 2017 Second Interna-onal Conference on Clinical Metagenomics (c) 2017, Fasteris SA

29